First Heart Rhythm Patients in Southern Italy Treated with Advanced Robotic Technology
Stereotaxis (NYSE: STXS) has announced that Hospital Santa Maria della Pietà in Nola, Southern Italy, has launched the region's first robotic cardiac heart program. The hospital has successfully treated patients with heart rhythm disorders using the Genesis Robotic Magnetic Navigation (RMN) system, making it the first in Italy to adopt this technology. Dr. Mario Volpicelli, Head of the Electrophysiology Unit, emphasized the precision and control offered by the Genesis RMN system in targeting arrhythmias, thereby minimizing patient risk. Tens of millions suffer from arrhythmias globally, which can increase risks of stroke, heart failure, and sudden cardiac arrest if untreated. General Manager Giuseppe Russo and Chief of Cardiology Luigi Caliendo praised the system for revolutionizing cardiac treatment in Italy. Stereotaxis Chairman and CEO David Fischel highlighted the partnership's commitment to advancing patient care and innovation in electrophysiology.
- Hospital Santa Maria della Pietà is the first in Italy to adopt the Genesis Robotic Magnetic Navigation (RMN) system.
- The advanced robotic technology provides unprecedented precision and control during cardiac ablation procedures.
- Minimizes risk to patients while targeting arrhythmias with unmatched accuracy.
- Marks a significant milestone in providing high standards of care in Southern Italy.
- Reflects a commitment to advancing standard of care, innovation, and patient-focused solutions in electrophysiology.
- No specific negative business aspects were mentioned in the press release.
The adoption of the Genesis Robotic Magnetic Navigation (RMN) system by Hospital Santa Maria della Pietà marks an important development in the treatment of cardiac arrhythmias. The precision afforded by robotic technology can significantly enhance the outcomes of cardiac ablation procedures, reducing the risk of complications and improving the accuracy of targeting arrhythmic tissues. This advancement is particularly relevant given the high prevalence of arrhythmias, which, if untreated, can lead to severe complications such as stroke and heart failure.
For patients, this means access to a higher standard of care and potentially better long-term health outcomes. The integration of robotics into medical procedures aligns with broader trends in healthcare towards minimally invasive techniques that offer faster recovery times and fewer risks compared to traditional methods. The successful implementation of this system in Southern Italy could pave the way for broader adoption across other regions, setting a new standard in electrophysiology treatments.
The deployment of the Genesis RMN system represents a significant step forward in the application of surgical robotics. Robotic Magnetic Navigation is at the cutting edge of technology, providing exceptional precision and control that are beyond the capabilities of human hands alone. By utilizing magnetic fields to guide the catheters, the system minimizes the mechanical stress on both the equipment and the patient, leading to safer procedures.
Moreover, this technology enhances the capabilities of electrophysiologists, allowing them to perform complex procedures with greater accuracy and consistency. This could translate into shorter procedure times and increased efficiency in the operating room, ultimately benefiting both patients and healthcare providers. Investors should note the potential for Stereotaxis to expand its market share as more hospitals adopt this state-of-the-art technology, reflecting positively on its growth prospects.
ST. LOUIS, May 22, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced that Hospital Santa Maria della Pietà, in Nola in the Metropolitan City of Naples, has established the first robotic cardiac heart program in Southern Italy. Patients suffering from heart rhythm disorders are now being successfully treated with robotic ablation procedures using this advanced technology, and Hospital Santa Maria della Pietà is the first hospital in Italy to adopt the cutting-edge Genesis Robotic Magnetic Navigation (RMN) system.
“As electrophysiologists, our primary goal is to improve the lives of our patients,” said Dr. Mario Volpicelli, Head of the Electrophysiology Unit of the hospital. “With the Genesis RMN system, we now have an unprecedented level of precision and control during cardiac ablation procedures, allowing us to target arrhythmias with unmatched accuracy while minimizing risk to our patients.”
Robotic Magnetic Navigation introduces the benefits of robotic precision and safety to cardiac ablation, a common minimally invasive procedure to treat arrhythmias. Tens of millions of individuals worldwide suffer from arrhythmias – abnormal heart rhythms that result when the heart beats too quickly, too slowly, or with an irregular pattern. When left untreated, arrhythmias may significantly increase the risk of stroke, heart failure, and sudden cardiac arrest.
"The adoption of the Genesis Robotic Magnetic Navigation system marks a significant milestone in our commitment to providing the highest standard of care to our patients.” added Giuseppe Russo, General Manager of the Hospital Santa Maria della Pietà.
“We are proud to lead the way in Italy, revolutionizing cardiac treatment through innovative robotic technology." added Luigi Caliendo, Chief of the Cardiology Department of the Hospital.
“We are honored to partner with Hospital Santa Maria della Pietà in bringing the benefits of robotics to patients in Italy,” said David Fischel, Stereotaxis Chairman and CEO. “The adoption of the Genesis system reflects our shared commitment to advancing standard of care, innovation, and patient-focused solutions in electrophysiology.”
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 100,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.
Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly Peery
Chief Financial Officer
314-678-6100
Investors@Stereotaxis.com
FAQ
What is the significance of Hospital Santa Maria della Pietà adopting the Genesis Robotic Magnetic Navigation system?
What are the benefits of the Genesis Robotic Magnetic Navigation (RMN) system in treating heart rhythm disorders?
How does the adoption of the Genesis system impact cardiac treatment in Southern Italy?
Who can benefit from the Genesis Robotic Magnetic Navigation system at Hospital Santa Maria della Pietà?
What is the role of Stereotaxis in the new cardiac heart program in Southern Italy?
